TScan Therapeutics Inc (TCRX) USD0.0001
Sell:$1.49Buy:$1.95
$0.12
(6.98%)
- This stock can be held in a
Stocks and Shares ISA$0.12
(6.98%)$0.12
(6.98%)Company Information
About this company
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Key people
Key facts
- EPICTCRX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS89854M1018
- Market cap$92.24m
- Employees194
- Shares in issue52.31m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.